JP Morgan Chase’s Champions Oncology CSBR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $64 | Hold |
11
| – | – | ﹤0.01% | 7342 |
|
|
2025
Q4 | $76 | Hold |
11
| – | – | ﹤0.01% | 7232 |
|
|
2025
Q3 | $71 | Hold |
11
| – | – | ﹤0.01% | 7196 |
|
|
2025
Q2 | $81 | Hold |
11
| – | – | ﹤0.01% | 6864 |
|
|
2025
Q1 | $95 | Hold |
11
| – | – | ﹤0.01% | 6885 |
|
|
2024
Q4 | $94 | Hold |
11
| – | – | ﹤0.01% | 7014 |
|
|
2024
Q3 | $54 | Hold |
11
| – | – | ﹤0.01% | 7110 |
|
|
2024
Q2 | $57 | Hold |
11
| – | – | ﹤0.01% | 7004 |
|
|
2024
Q1 | $54 | Sell |
11
-89
| -89% | -$521 | ﹤0.01% | 7016 |
|
|
2023
Q4 | $541 | Buy |
100
+89
| +809% | +$496 | ﹤0.01% | 6912 |
|
|
2023
Q3 | $68 | Hold |
11
| – | – | ﹤0.01% | 6957 |
|
|
2023
Q2 | $69 | Hold |
11
| – | – | ﹤0.01% | 6719 |
|
|
2023
Q1 | $0 | Hold |
11
| – | – | ﹤0.01% | 6770 |
|
|
2022
Q4 | $0 | Hold |
11
| – | – | ﹤0.01% | 6608 |
|
|
2022
Q3 | $0 | Hold |
11
| – | – | ﹤0.01% | 6506 |
|
|
2022
Q2 | $0 | Hold |
11
| – | – | ﹤0.01% | 6521 |
|
|
2022
Q1 | $0 | Hold |
11
| – | – | ﹤0.01% | 6652 |
|
|
2021
Q4 | $0 | Hold |
11
| – | – | ﹤0.01% | 6686 |
|
|
2021
Q3 | $0 | Sell |
11
-4,368
| -100% | -$44.4K | ﹤0.01% | 6520 |
|
|
2021
Q2 | $45K | Sell |
4,379
-15,908
| -78% | -$161K | ﹤0.01% | 5761 |
|
|
2021
Q1 | $229K | Buy |
20,287
+1,460
| +8% | +$16.9K | ﹤0.01% | 5095 |
|
|
2020
Q4 | $203K | Buy |
18,827
+7,687
| +69% | +$79.3K | ﹤0.01% | 4802 |
|
|
2020
Q3 | $103K | Sell |
11,140
-1,933
| -15% | -$17.2K | ﹤0.01% | 4675 |
|
|
2020
Q2 | $125K | Buy |
13,073
+10,820
| +480% | +$92.2K | ﹤0.01% | 4472 |
|
|
2020
Q1 | $17K | Buy |
+2,253
| New | +$15.8K | ﹤0.01% | 4976 |
|
|
2018
Q4 | – | Sell |
-123,770
| Closed | -$2.16M | – | 5719 |
|
|
2018
Q3 | $2.16M | Buy |
+123,770
| New | +$1.1M | ﹤0.01% | 3412 |
|
|
2017
Q4 | – | Sell |
-2,500
| Closed | -$10K | – | 5449 |
|
|
2017
Q3 | $10K | Hold |
2,500
| – | – | ﹤0.01% | 4717 |
|
|
2017
Q2 | $6K | Hold |
2,500
| – | – | ﹤0.01% | 4733 |
|
|
2017
Q1 | $8K | Buy |
+2,500
| New | +$8.75K | ﹤0.01% | 4837 |
|
|
2016
Q1 | – | Sell |
-675
| Closed | -$2K | – | 4697 |
|
|
2015
Q4 | $2K | Buy |
+675
| New | +$2.9K | ﹤0.01% | 4513 |
|
Other funds holding CSBR
BMC
NMC
TAM
VCM
MBAM
JP Morgan Chase's CSBR Position: Q1 2026 in Review
JP Morgan Chase held its Champions Oncology (CSBR) position steady in Q1 2026 at 11 shares worth $64. The position accounts for ﹤0.01% of the portfolio, ranked #7342.
JP Morgan Chase first reported a position in CSBR in Q4 2015 and has held it in 30 quarters since. The position peaked at $2.16M in Q3 2018. 25 funds tracked by Wall St. Rank hold CSBR as of Q1 2026.
- JP Morgan Chase held 11 shares of Champions Oncology worth $64 as of Q1 2026.
- JP Morgan Chase left its Champions Oncology share count unchanged in Q1 2026.
- Champions Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7342 holding.
- JP Morgan Chase first reported a position in Champions Oncology in Q4 2015 and has held it in 30 quarters since.
- JP Morgan Chase's Champions Oncology position peaked at $2.16M in Q3 2018.
- 25 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.